NCT03319849: A trial that was reported late by Neurotech Pharmaceuticals
This trial has reported, although it was 328 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03319849 |
|---|---|
| Title | A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 22, 2018 |
| Completion date | Aug. 31, 2022 |
| Required reporting date | Aug. 31, 2023, midnight |
| Actual reporting date | July 24, 2024 |
| Date last checked at ClinicalTrials.gov | April 7, 2025 |
| Days late | 328 |